SCHEDULE: STAAR Surgical Appoints Christopher Wang to Board

STAAR Surgical Company announced the appointment of Christopher Min Fang Wang to its Board of Directors following a cooperation agreement with Broadwood Partners, L.P.

Summary

• STAAR Surgical Co. entered into a Cooperation Agreement with Broadwood Partners, L.P. on January 14, 2026.
• As a result of this agreement, Christopher Min Fang Wang was appointed to the Issuer's Board of Directors, effective January 14, 2026.
• Christopher Min Fang Wang, along with Yunqi Capital Limited and Yunqi Capital Cayman Limited, beneficially owns 3,257,130 shares of STAAR Surgical Co. common stock, representing 6.5% of the class.
• Yunqi Path Capital Master Fund beneficially owns 2,575,061 shares, representing 5.2% of the class.
• Yunqi China Special Investment A, HS Group Master Fund II Ltd, HS Group (Hong Kong) Limited, and HS Group Ltd each beneficially own 682,069 shares, representing 1.4% of the class.

Sentiment

Score: 7

Explanation: The filing indicates a positive development in corporate governance through a cooperation agreement and board appointment, suggesting improved shareholder representation and potential for strategic alignment. No negative financial or operational news is present.

Positives

• The appointment of Christopher Min Fang Wang to the Board of Directors enhances shareholder representation, particularly for the Yunqi Capital and Broadwood Partners groups.
• The Cooperation Agreement suggests a constructive engagement between a significant shareholder and the company's management, potentially leading to strategic alignment.

Future Outlook

The appointment of a new director from a significant shareholder group suggests potential future strategic input and oversight, aligning the interests of the company with a key investor.

Industry Context

In the ophthalmic medical device industry, corporate governance and strategic direction are crucial for innovation and market penetration. The addition of a director representing a major shareholder group can influence the company's approach to product development, market expansion, and capital allocation, potentially impacting its competitive standing against peers.

Management Changes

Corporate Governance

Stakeholder Impact

• Shareholders: The appointment of a director representing a significant shareholder group may lead to increased oversight and strategic decisions more aligned with shareholder interests.
• Management: The addition of a new board member will introduce new perspectives and potentially influence strategic discussions and operational priorities.

Key Dates

Recommendation

The appointment of Christopher Min Fang Wang to the Board of Directors, stemming from a cooperation agreement with Broadwood Partners, L.P., signals enhanced shareholder representation and potential for strategic alignment. While this is a positive governance development, the filing lacks specific financial or operational updates to warrant a 'buy' or 'sell' recommendation. Investors should 'hold' and monitor future strategic directions and financial performance.

Keywords

STAAR Surgical, Board of Directors, Corporate Governance, Schedule 13D, Shareholder Activism, Broadwood Partners, Christopher Min Fang Wang, Ophthalmology, Medical Devices